Published on 21/12/2025
Step-by-Step Guide to Designing and Executing Basket Trials in Oncology
Introduction to Basket Trials
Basket trials represent a groundbreaking approach in oncology, allowing a single investigational drug to be tested across multiple tumor types that share a common molecular alteration. Instead of focusing on where the cancer originates, basket trials focus on the genetic or molecular signature of the tumor. This tumor-agnostic approach has already led to landmark drug approvals, such as TRK inhibitors for NTRK fusion-positive cancers.
The flexibility of basket trials enables the inclusion of rare tumor types, which traditionally face recruitment challenges in conventional trial designs. Regulatory agencies like the FDA and EMA recognize their potential but require strict statistical and operational frameworks to ensure valid, reliable results.
Regulatory Considerations for Basket Trials
The regulatory landscape for basket trials is evolving, with guidelines emphasizing:
- Independent statistical evaluation of each tumor type cohort.
- Biomarker assay validation before patient enrollment.
- Clear justification for pooling results across tumor types when appropriate.
ICH E6(R3) and ICH E8(R1) provide the overarching Good Clinical Practice (GCP) framework, while the FDA’s draft guidance on master protocols outlines specific expectations for tumor-agnostic study designs.
Statistical Design in Basket Trials
Basket trials typically
Dummy Table: Basket Trial Cohort Overview
| Cohort | Tumor Type | Biomarker | Sample Size | Primary Endpoint |
|---|---|---|---|---|
| A | Colorectal | NTRK fusion | 30 | ORR |
| B | NSCLC | NTRK fusion | 40 | PFS |
| C | Thyroid | NTRK fusion | 20 | ORR |
Bayesian adaptive designs are frequently used to allow early stopping for futility or expansion based on promising early data.
Operational Execution
Operationalizing a basket trial involves several key steps:
- Biomarker Screening: Implement broad genomic profiling to identify eligible patients across tumor types.
- Centralized Laboratory Testing: Ensure consistent limit of detection (LOD) and limit of quantification (LOQ) for biomarker assays.
- Rolling Cohort Activation: Open new cohorts as scientific evidence emerges.
- Supply Chain Coordination: Manage investigational product distribution across multiple cancer types and sites.
Operational best practices and SOP templates for basket trials are available from resources like PharmaValidation.in, ensuring GxP-compliant trial management.
Regulatory Submission Pathways
Tumor-agnostic approvals based on basket trials are often granted through accelerated approval pathways, requiring robust post-marketing confirmatory trials. Sponsors should engage with regulators early, ideally before finalizing the statistical analysis plan, to align expectations for data pooling and cohort-specific outcomes.
Key submission considerations include:
- Separate clinical study reports (CSRs) for each cohort.
- Integrated summaries of efficacy and safety where appropriate.
- Documentation of biomarker assay performance across tumor types.
Case Study: Larotrectinib Basket Trial
Larotrectinib’s tumor-agnostic approval in NTRK fusion-positive cancers is a leading example of basket trial success. The trial enrolled patients across more than 15 tumor types, demonstrating consistently high overall response rates (ORR) and durable responses, which met both FDA and EMA requirements for accelerated approval.
Advantages and Limitations
Advantages:
- Efficient drug development for rare molecular subtypes.
- Potential for tumor-agnostic regulatory approval.
- Simultaneous evaluation of multiple cancer types.
Limitations:
- Small sample sizes in rare tumor cohorts.
- Complex regulatory and statistical planning.
- Potential heterogeneity in treatment effect across tumor types.
Conclusion
Basket trials are redefining the landscape of oncology drug development by focusing on molecular drivers rather than tumor origin. With careful regulatory planning, rigorous statistical design, and coordinated operational execution, they can deliver rapid access to transformative therapies for patients with rare and challenging cancers.